Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Subscribe To Our Newsletter & Stay Updated
